[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"upper-respiratory-tract-infection-urti\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:upper-respiratory-tract-infection-urti":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,43],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100653414","effect-of-immune-x-on-common-cold-incidence-in-healthy-adults-100653414",false,"NCT07787130","Effect of Immune X on Common Cold Incidence in Healthy Adults","The Effect of Immune X on the Incidence of the Common Cold in Healthy Adults: A Randomized, Double-Blind, Placebo-Controlled Trial","CELFI","Inclusion Criteria:\n\n* Men and women aged 18 to 65 years.\n* History of at least two upper respiratory tract infections during the previous winter season.\n* Body mass index between 18 and 30 kg\u002Fm².\n* Generally healthy, as determined by the investigator.\n* Women of childbearing potential must have a negative pregnancy test and agree to use an effective method of contraception during the study.\n* Covered by French health insurance.\n* Able and willing to provide written informed consent.\n\nExclusion Criteria:\n\n* Current or recent upper respiratory tract infection or COVID-19 infection within 2 weeks before enrollment.\n* Acute gastrointestinal infection, including gastroenteritis, within 2 weeks before enrollment.\n* Use of non-steroidal anti-inflammatory drugs (NSAIDs) within 2 weeks before enrollment.\n* Use of systemic antibiotics within 3 months before enrollment.\n* Receipt of any vaccination within 6 weeks before enrollment.\n* Surgery requiring general anesthesia within 1 month before enrollment.\n* History of chronic respiratory disease, including asthma or chronic obstructive pulmonary disease.\n* Food allergy or chronic\u002Frecurrent allergic upper airway conditions requiring regular medical treatment, including moderate to severe allergic rhinitis, hay fever, or chronic rhinosinusitis.\n* Acute lower respiratory tract infection within 6 months before enrollment or ongoing long COVID.\n* Immunodeficiency (including HIV infection) or autoimmune disease, except stable hypothyroidism.\n* Severe or uncontrolled chronic disease, including cancer, significant liver, pancreatic, biliary, or renal disease, inflammatory bowel disease, or cardiovascular disease requiring intensive medical management.\n* Untreated or inadequately controlled diabetes.\n* History or current diagnosis of periodontitis.\n* Current chemotherapy, immunosuppressive therapy, or chronic treatment with corticosteroids or opioids.\n* Specific diets or major dietary changes within 3 months before enrollment, including high-protein, vegan, low-calorie, or low-FODMAP diets, or participation in a weight-loss program.\n* Current use of dietary supplements that may affect immune or gut microbiota parameters, or discontinuation of such supplements less than 6 weeks before enrollment.\n* Current smoking or e-cigarette use, or smoking cessation within 6 months before enrollment.\n* Current drug or alcohol abuse, or a history of abuse within the previous 12 months.\n* Regular consumption of more than 2 alcoholic drinks per day and unwillingness to maintain stable drinking habits during the study.\n* Unwillingness to refrain from using over-the-counter cold remedies, nasal washes or sprays, antihistamines, corticosteroids, or NSAIDs during the study.\n* More than 8 hours per week of vigorous physical activity or planned major changes in physical activity during the study.\n* Any condition or circumstance that, in the investigator's judgment, may place the participant at unacceptable risk or interfere with study participation or interpretation of study results.\n* Current participation in another clinical trial or being in an exclusion period from a previous clinical trial.\n* Pregnant or breastfeeding.\n* Persons deprived of liberty, under legal protection, or unable to provide informed consent.\n* Individuals who have reached the regulatory compensation limit for participation in clinical research.",true,"ALL","18 Years","65 Years",{"count":22,"type":23},160,"ESTIMATED","INTERVENTIONAL",[26],"NA","The goal of this clinical trial is to learn if Immune X can help prevent common cold events in healthy adults who have a history of upper respiratory tract infections. The main questions it aims to answer are:\n\n* Does Immune X reduce the proportion of participants who experience at least one clinically confirmed common cold event during the study period?\n* Does Immune X affect the number, duration, and severity of common cold events?\n\nResearchers will compare Immune X to a placebo (a look-alike capsule containing inactive ingredients) to see if Immune X helps prevent common cold events.\n\nParticipants will:\n\n* Take Immune X or placebo daily for 16 weeks during the winter season.\n* Attend study visits at the beginning and end of the study and complete questionnaires and symptom assessments throughout the study.\n* Record cold symptoms, medications, and other study information using a smartphone application.\n* Provide blood and stool samples during the study.",[29,30],"Common Cold","Upper Respiratory Tract Infection (URTI)","RECRUITING","2026-10-09",{"date":34,"type":35},"2026-10-13","ACTUAL",{"date":32,"type":35},{"date":38,"type":23},"2027-03-01",{"name":40,"class":41},"Givaudan France Naturals","INDUSTRY",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":17,"sex":18,"minAge":50,"maxAge":19,"enrollmentInfo":51,"targetDuration":4,"studyType":24,"phases":53,"briefSummary":54,"conditions":55,"keywords":56,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":5},"100657161","probiotics-for-sustained-health-100657161","NCT07835100","Probiotics for Sustained Health","A Pilot Study; a Randomized Double-blind Placebo-controlled Study to Investigate a Probiotic Supplement on Symptoms of Upper Respiratory Tract Infections","Inclusion Criteria:\n\n* Age 4 to18 years\n* Male or female\n* Healthy (no known chronic disease)\n* At least 3 episodes of Upper Respiratory Tract Infection (pharyngitis and or tonsillitis, cold, rhinitis, sinusitis) in the previous year\n* Written informed consent signed by both parents or caregivers\n\nExclusion Criteria:\n\n* Use of antibiotics or probiotic products 2 weeks prior inclusion in the study\n* Use of two or more consecutive months on antibiotics for respiratory infections on the last year\n* Participation in another clinical trial\n* Parents or caregivers unable to read, understand and follow the instructions","4 Years",{"count":52,"type":23},70,[26],"This randomized, double-blind, placebo-controlled pilot study will evaluate the effect of a probiotic supplement on upper respiratory tract infections (URTIs) in children aged 4-18 years with a history of recurrent URTIs. Participants will be randomized to receive either probiotic drops or placebo drops. The primary objective is to assess the effect of the probiotic on the frequency of URTI episodes during the study period. Secondary objectives include evaluation of respiratory symptoms, medication use, healthcare visits, school absenteeism, recovery of the administered probiotic, and safety.",[30],[57,30],"Probiotics","NOT_YET_RECRUITING","2026-09-22",{"date":61,"type":35},"2026-09-24",{"date":63,"type":23},"2026-09-25",{"date":65,"type":23},"2028-04-30",{"name":67,"class":41},"BioGaia AB"]